Trial Search Results

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.

There is no recommended standard treatment for relapsed or refractory acute myelogenous leukemia in older patients. Cytarabine is the most commonly used drug to treat these patients. This study will determine if there is benefit by combining clofarabine with cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either placebo in combination with cytarabine or clofarabine in combination with cytarabine. Randomization was stratified by remission status following the first induction regimen (no remission [i.e., CR1 = refractory] or remission <6 months vs CR1 = remission ≥6 months). CR1 is defined as remission after first pre-study induction regimen. The safety and tolerability of clofarabine in combination with cytarabine and cytarabine alone will be monitored throughout the study.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Genzyme, a Sanofi Company

Stanford Investigator(s):


  • Drug: clofarabine (IV formulation)
  • Drug: placebo
  • Drug: cytarabine


Phase 3


Inclusion Criteria:

   - Have a diagnosis of Acute Myelogenous Leukemia (AML) according to World Health
   Organization (WHO) classification

   - Relapsed after receiving up to 2 prior induction regimens (i.e. first or second
   relapse)or are refractory to not more than one prior combination chemotherapy
   induction regimen

   - Be ≥ 55 years of age

   - Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2

   - Be able to comply with study procedures and follow-up examinations

   - Be nonfertile or agree to use birth control during the study through the end of
   treatment visit and for at least 90 days after the last dose of study drug

   - Have adequate liver and renal function as indicated by certain laboratory values

Exclusion Criteria:

   - Received previous treatment with clofarabine

   - Received bolus, intermediate or high-dose cytarabine as induction therapy unless
   certain remission criteria are met

   - Have received a hematopoietic stem cell transplant (HSCT) within the previous 3 months

   - Have moderate or severe graft versus host disease (GVHD), whether acute or chronic

   - Are receiving any other chemotherapy or investigational therapy. Patients must have
   been off prior AML therapy for at least 2-6 weeks prior to entering study.

   - Have a psychiatric disorder that would interfere with consent, study participation, or

   - Have an active, uncontrolled infection

   - Have any other severe concurrent disease, or have a history of serious organ
   dysfunction or disease involving the heart, kidney, liver, or other organ system

   - Have been diagnosed with another malignancy, unless disease-free for at least 5 years;
   patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical
   intraepithelial neoplasia, regardless of the disease-free duration, are eligible for
   this study if definitive treatment for the condition has been completed; patients with
   organ-confined prostate cancer with no evidence of recurrent or progressive disease
   are eligible if hormonal therapy has been initiated or the malignancy has been
   surgically removed.

   - Have clinical evidence suggestive of central nervous system (CNS) involvement with
   leukemia unless lumbar puncture confirms absence of leukemic blasts in the
   cerebrospinal fluid(CSF)

   - Known HIV positivity

   - Are pregnant or lactating

Ages Eligible for Study

55 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Richa Rajwanshi
Not Recruiting